MedTrace Logo

Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea.

NCT00812188 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-02-18

No results posted yet for this study

Summary

Compare UVA-1 phototherapy treatment to topical steroid treatment in subjects with morphea.

Conditions

  • Symmetric Limited Morphea

Interventions

OTHER

Medium Dose UVA-1

UVA-1 phototherapy treatment (60 J/cm2) three times per week for 12 weeks.

OTHER

High Dose UVA-1

High dose (120 J/cm2)UVA-1 phototherapy three times per week for 12 weeks.

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Heidi Jacobe, M.D. · UT Southwestern Medical Center at Dallas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00812188 on ClinicalTrials.gov